Morgan Stanley Keeps Their Hold Rating on Abbott Laboratories (ABT)
Nephron Adjusts Price Target on Abbott Laboratories to $110 From $115
Baird Maintains Outperform on Intuitive Surgical, Raises Price Target to $503
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
Morgan Stanley Adjusts Price Target on Intuitive Surgical to $475 From $460, Maintains Equalweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Maintained Buy Rating for Abbott Laboratories on Strong Financials and Growth Prospects
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
Buy Rating Affirmed on Abbott Laboratories Amid Strong Q2 Results and Raised 2024 Guidance
Intuitive Surgical Analyst Ratings
Buy Rating Affirmed for Abbott Laboratories Amid Strong Financials and Growth Potential
Barclays Remains a Buy on Intuitive Surgical (ISRG)
Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials
Leerink Adjusts Price Target on DexCom to $151 From $161
BNP Paribas Exane Initiates GE HealthCare Technologies at Outperform With $92 Price Target
Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $85
Medtronic Analyst Ratings
Edwards Lifesciences Analyst Ratings
Baird Adjusts Price Target on Intuitive Surgical to $487 From $436, Maintains Outperform Rating
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $589 From $596, Maintains Overweight Rating